Combinative treatment of transarterial chemoembolization, celecoxib and lanreotide in unresectable hepatocellular carcinoma

Clin Res Hepatol Gastroenterol. 2015 Oct;39(5):e65-6. doi: 10.1016/j.clinre.2015.01.008. Epub 2015 Mar 4.

Authors

Huan Tong¹, Xiao Li¹, Bo Wei¹, Chengwei Tang²

Affiliations

¹ Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
² Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China. Electronic address: shcqcdmed@163.com.

PMID: 25746137
DOI: 10.1016/j.clinre.2015.01.008

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Hepatocellular / drug therapy*
Carcinoma, Hepatocellular / pathology
Celecoxib / administration & dosage
Chemoembolization, Therapeutic* / methods
Hepatic Artery
Humans
Injections, Intra-Arterial
Liver Neoplasms / drug therapy*
Liver Neoplasms / pathology
Male
Middle Aged
Neoplasm Invasiveness
Neoplasm Staging
Peptides, Cyclic / administration & dosage
Prognosis
Somatostatin / administration & dosage
Somatostatin / analogs & derivatives
Treatment Outcome

Substances

Peptides, Cyclic
lanreotide
Somatostatin
Celecoxib